Positive Surgical Margins Linked to Worse RCC Recurrence, Survival Rates
Findings may inform treatment decisions after nephrectomy with positive surgical margins.
Diagnosis & Disease Information
Fat Loss Portends Worse Prognosis in ICI-Treated Metastatic Clear Cell RCC
Change in subcutaneous fat after initiation of immune checkpoint inhibitors may distinguish which patients will and will not respond to therapy.
Partial Cytoreductive Nephrectomy Still Offers Survival Edge in Metastatic RCC
Partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
Benefits Persist for Lenvatinib Plus Pembrolizumab in Renal Cell Cancer
Lenvatinib plus pembrolizumab improved outcomes vs sunitinib in patients with advanced renal cell carcinoma.
RCC Stratification System May Need to Be Refined, Data Suggest
Investigators concluded that pN1 RCC could be stratified into pN1 and pN2, with pN2 conferring a poor prognosis comparable to that of non-metastatic stage IV pN0 disease.
Certain Antibiotics May Reduce the Efficacy of Certain ICIs in Cancer Patients
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
Identifying and Managing Adverse Reactions to Lenvatinib and Pembrolizumab
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
Imaging With 89Zr-DFO-Girentuximab Identifies Clear Cell Renal Cell Carcinoma
A novel imaging technique, 89Zr-DFO-girentuximab PET/CT, can accurately and noninvasively identify clear cell renal cell carcinoma, a study suggests.
Cabozantinib Shows Activity in Advanced RCC After CPI-Based Combinations
Cabozantinib can produce responses in patients with advanced clear cell RCC whose disease progressed on first-line checkpoint inhibitor-based therapy, a phase 2 study suggests.
HRQOL Outcomes Superior With Higher Lenvatinib Starting Dose in RCC
A higher starting dose of lenvatinib is associated with better health-related quality of life in patients with renal cell carcinoma.
- Loading...
Loading...
Next post in Renal Cell Carcinoma
Loading... 
Loading...